Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Neoplasms by Histologic Type

• Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors
• Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
• Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
• DETERMINE Trial Treatment Arm 3: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.
• DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficie
• DETERMINE Trial Treatment Arm 1: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers
• A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver
• Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture
• A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
• Anrotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
• Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
• Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
• A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
• Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
• Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
• A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
• (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
• Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
• Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
• Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
• P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
• Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma
• Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
• Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma
• Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
• Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
• Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
• Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
• Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
• A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
• A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
• A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
• Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
• A Trial In Patients With Advanced Cancer And Leukemia
• A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma